Rifaximin Reduces the Risk of Hospitalizations in Patients with Previous Episodes of Hepatic Encephalopathy: Results from a Phase 3 Placebo-Controlled Trial

被引：0
|
作者：
Neff, Guy
Leevy, Carroll B.
Frederick, Todd
Merchant, Kunal
Huang, Shirley
Shaw, Audrey L.
Forbes, William P.
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A11 / A12
页数：2
相关论文
共 50 条
  • [11] Effect of rifaximin in severe cirrhotic patients with ascites: a double-blind randomized placebo-controlled phase 3 trial
    Thevenot, Thierry
    Elkrief, Laure
    Bureau, Christophe
    Bardou-Jacquet, Edouard
    Rosa, Isabelle
    Khac, Eric Nguyen
    Oberti, Frederic
    Pitta, Anais
    Mallet, Maxime
    Lebosse, Fanny
    Louvet, Alexandre
    Meunier, Lucy
    Nahon, Pierre
    Ollivier-Hourmand, Isabelle
    Anty, Rodolphe
    Francoz, Claire
    Riachi, Ghassan
    Meunier, Alexandre
    Tio, Gregory
    Muller, Allison
    Cure-Martin, Audace
    Hocquet, Didier
    Di Martino, Vincent
    Weil-Verhoeven, Delphine
    Desmarets, Maxime
    JOURNAL OF HEPATOLOGY, 2024, 80 : S61 - S62
  • [12] Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial
    Bajaj, Jasmohan S.
    Salzman, Nita H.
    Acharya, Chathur
    Sterling, Richard K.
    White, Melanie B.
    Gavis, Edith A.
    Fagan, Andrew
    Hayward, Michael
    Holtz, Mary L.
    Matherly, Scott
    Lee, Hannah M.
    Osman, Majdi
    Siddiqui, Mohammad S.
    Fuchs, Michael
    Puri, Puneet
    Sikaroodi, Masoumeh
    Gillevet, Patrick M.
    HEPATOLOGY, 2019, 70 (05) : 1690 - 1703
  • [13] Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study
    Sanyal, A.
    Younossi, Z. M.
    Bass, N. M.
    Mullen, K. D.
    Poordad, F.
    Brown, R. S.
    Vemuru, R. P.
    Jamal, M. Mazen
    Huang, S.
    Merchant, K.
    Bortey, E.
    Forbes, W. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (08) : 853 - 861
  • [14] Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial
    Bruno, Benjamin J.
    Weavil, Joshua C.
    Ogle, Jonathan
    Chidambaram, Nachiappan
    Carey, Elizabeth J.
    Danford, Christopher J.
    Fricker, Zachary P.
    Galati, Joseph S.
    Lee, William M.
    Mantry, Parvez S.
    Shetty, Kirti
    Delconte, Anthony
    Patel, Mahesh V.
    Lai, Jennifer C.
    Sanyal, Arun J.
    HEPATOLOGY, 2025,
  • [15] Rifaximin maintained remission from hepatic encephalopathy longer than placebo in patients with cirrhosis
    Story, Brian T.
    Kowdley, Kris V.
    ANNALS OF INTERNAL MEDICINE, 2010, 153 (04)
  • [16] Golimumab Reduces Sleep Disturbance in Patients With Active Ankylosing Spondylitis: Results From a Randomized, Placebo-Controlled Trial
    Deodhar, Atul
    Braun, Juergen
    Inman, Robert D.
    Mack, Michael
    Parasuraman, Shreekant
    Buchanan, Jacqueline
    Hsu, Benjamin
    Gathany, Tim
    van der Heijde, Desiree
    ARTHRITIS CARE & RESEARCH, 2010, 62 (09) : 1266 - 1271
  • [17] Sutimlimab in patients with cold agglutinin disease results of the randomized placebo-controlled phase 3 CADENZA trial
    Roeth, Alexander
    Berentsen, Sigbjorn
    Barcellini, Wilma
    D'Sa, Shirley
    Jilma, Bernd
    Michel, Marc
    Weitz, Ilene C.
    Yamaguchi, Masaki
    Nishimura, Jun-ichi
    Vos, Josephine M., I
    Storek, Michael
    Wong, Nancy
    Patel, Parija
    Jiang, Xiaoyu
    Vagge, Deepthi S.
    Wardecki, Marek
    Shafer, Frank
    Lee, Michelle
    Broome, Catherine M.
    BLOOD, 2022, 140 (09) : 980 - 991
  • [18] Rifaximin Improves Cognitive Functions and Health-Related Quality of Life in Patients With Minimal Hepatic Encephalopathy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial (The RIME Trial)
    Sidhu, Sandeep
    Goyal, Omesh
    Mishra, Bholeshwar P.
    Sood, Ajit
    Chhina, Rajoo S.
    Soni, Ravinder K.
    GASTROENTEROLOGY, 2010, 139 (01) : E18 - E19
  • [19] Rifaximin reduces healthcare utilization but not overall costs in patients with cirrhosis and recurrent episodes of hepatic encephalopathy: a retrospective efficacy study
    van Doorn, Diederick
    van Eekhout, Kirsi
    de Wit, Koos
    Baak, L. C.
    Klemt-Kropp, Michael
    Verwer, Bart
    Friederich, Philip W.
    de Bruin, Gijs J.
    Vos, Xander
    Takkenberg, R. Bart
    JOURNAL OF HEPATOLOGY, 2024, 80 : S213 - S214
  • [20] A RANDOMIZED TRIPLE BLIND, PLACEBO- CONTROLLED TRIAL TO DETERMINE EFFECTIVENESS OF RIFAXIMIN IN PREVENTING HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CHRONIC LIVER DISEASE
    Aqeel, Abdur Rehman
    Butt, Binyamin
    Naveed, Hira
    Arshad, Ali
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (04): : 2728 - 2732
12345